Equities research analysts at Stephens began coverage on shares of Amedisys (NASDAQ:AMED) in a research report issued to clients and investors on Monday, The Fly reports. The brokerage set an “equal weight” rating on the health services provider’s stock.
Several other brokerages have also commented on AMED. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. Royal Bank of Canada increased their price objective on Amedisys to $150.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. ValuEngine lowered Amedisys from a “buy” rating to a “hold” rating in a report on Thursday, September 26th. Barclays increased their price objective on Amedisys from $120.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 5th. Finally, Deutsche Bank assumed coverage on Amedisys in a report on Monday, September 16th. They set a “buy” rating and a $155.00 price objective for the company. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $141.80.
Amedisys stock opened at $134.79 on Monday. The business has a fifty day moving average of $131.09 and a two-hundred day moving average of $125.10. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.58. The firm has a market cap of $4.35 billion, a P/E ratio of 37.13, a P/E/G ratio of 2.01 and a beta of 1.44. Amedisys has a twelve month low of $97.38 and a twelve month high of $141.98.
In related news, Director Jake L. Netterville sold 1,000 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $135.64, for a total value of $135,640.00. Following the completion of the transaction, the director now owns 72,700 shares in the company, valued at approximately $9,861,028. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Christopher Gerard sold 350 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $128.79, for a total value of $45,076.50. Following the completion of the transaction, the chief operating officer now owns 25,239 shares of the company’s stock, valued at approximately $3,250,530.81. The disclosure for this sale can be found here. Insiders sold a total of 11,849 shares of company stock valued at $1,569,388 in the last 90 days. 2.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Rehmann Capital Advisory Group acquired a new stake in Amedisys during the 2nd quarter worth about $31,000. CWM LLC grew its position in Amedisys by 482.2% during the 2nd quarter. CWM LLC now owns 262 shares of the health services provider’s stock worth $32,000 after purchasing an additional 217 shares during the period. Tompkins Financial Corp acquired a new stake in Amedisys during the 2nd quarter worth about $37,000. Point72 Asset Management L.P. acquired a new stake in Amedisys during the 2nd quarter worth about $49,000. Finally, Maverick Capital Ltd. acquired a new stake in Amedisys during the 2nd quarter worth about $54,000. Institutional investors own 88.60% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Recommended Story: Percentage Decliners
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.